Search research articles
Contact Us
Filters
Showing results (351-360 of 418) with videos related to
Page
of 42
Sort By:
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Cancer Discovery
|
November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Communications
|
July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumors
Lei Guan, Bin Wu, Ting Li, et al.
Nature Communications
|
October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Jesse Fajnzylber, James Regan, Kendyll Coxen, et al.
Cancer Immunology Research
|
January 9, 2025
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Yi Sun, Luke Maggs, Apekshya Panda, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
F Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Cancer Discovery
|
December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Page
of 42
Search research articles
Search
Showing results (351-360 of 418) with videos related to
Sort By:
Page
of 42
JCO Precision Oncology
|
April 13, 2023
Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Kari B Wisinski, Yael Flamand, Melissa A Wilson, et al.
Cancer Discovery
|
November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition
Nikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
JCO Precision Oncology
|
October 9, 2025
Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T
Anne S Tsao, Zihe Song, Alan L Ho, et al.
Nature Communications
|
July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumors
Lei Guan, Bin Wu, Ting Li, et al.
Nature Communications
|
October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortality
Jesse Fajnzylber, James Regan, Kendyll Coxen, et al.
Cancer Immunology Research
|
January 9, 2025
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Yi Sun, Luke Maggs, Apekshya Panda, et al.
Nature Medicine
|
June 15, 2023
The NCI-MATCH trial: lessons for precision oncology
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2021
Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i>-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i>-Mutated Tumors
James M Cleary, Victoria Wang, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
F Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Cancer Discovery
|
December 20, 2018
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha, Nektaria M Leli, Angelique Onorati, et al.
Page
of 42